Pliant Therapeutics Inc. said that PLN-74809, its oral, dual-selective integrin inhibitor, has received fast track designation from the U.S. Food and Drug Administration for the potential treatment of idiopathic pulmonary fibrosis.
The company said PLN-74809 is currently being tested as part of a Phase 2a clinical trial.
Pliant said it anticipates topline data from this randomized, double-blind, placebo-controlled trial in patients with idiopathic pulmonary fibrosis in mid-2022.
FDA's fast track designation is intended to speed up the development and review of new drugs to treat serious or life-threatening conditions.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.